Price Action · 24 Months
Visional declined −7% while TOPIX returned +49% over the same period. This drawdown is alpha, not beta — the question is what the market repriced and why.
A · APR–AUG 2025 · +67% The rally was a regime change in narrative, not a single print. Q3 FY7/25 results (June 2025) showed BizReach scaling at +19% YoY with 42.7% segment OPM while HRMOS — three years of investment with no profit — crossed into the black on a YTD basis with ARR through ¥8.95bn. That is the textbook moment a platform compounder gets re-rated: the profit engine is still working, and a second engine has just started turning. The August peak at ¥12,310 anchored a ~14x forward EV/EBIT — a multiple Visional had never previously sustained, paid in anticipation of the FY7/25 full-year print.
B · AUG 2025 – FEB 2026 · −48% The unwind was not a missed result. The September full-year FY7/25 print landed solidly and FY7/26 guidance was raised. What broke the rally was the composition of that guide: management was explicit that operating profit would grow slower than the top-line because reinvestment in Internal BizReach, the Thinkings/sonar ATS integration, and Incubation businesses was being front-loaded. By the Q1 FY7/26 release in December, the worst case was being confirmed — the chart had priced accelerating margin, the disclosures showed compressing margin. Two cycles then compounded the de-rate. Cycle one: consensus could not separate organic HRMOS profitability from the sonar ATS consolidation effect — a single decimal of disclosure was missing, and the market priced the worst case. Cycle two: Japan domestic hiring sentiment turned cautious through Q4-CY25 on the BOJ rate path; BizReach correlates positively with enterprise hiring confidence, and that beta got repriced.
ALPHA vs BETA Critically, this drawdown is company-specific, not sector-driven. Over the same 24 months Visional declined −7% while TOPIX returned +49% — an implied 56-percentage-point underperformance against the broad market. The "this is the cycle" framing does not hold; HR Tech sector betas explain almost none of the move. What was repriced is the multiple investors are willing to pay for disclosed-but-ambiguous capital efficiency.
C · MAR 2026 · +16% OFF FLOOR The Q2 FY7/26 release on 17 March reset the worst case: 2Q YTD sales ¥46.61bn (+26.2% YoY), HR Tech segment OPM held at 33%, HRMOS profitable on both YTD and quarterly bases, ARR through ¥8.95bn, full-year guidance unchanged. The market answered with +16% off the ¥6,347 floor. The recovery has restored confidence in the engine but not in the multiple. The gap from today's ¥7,337 to the August peak is no longer an earnings question — it is a disclosure question. Until investors can separate organic HRMOS profitability from M&A-driven uplift, the multiple stays in the 8x EV/EBIT zone, not the 14x zone.
Live Investor Debates
Three open debates currently visible in sell-side reports, IR Q&A, and price action. Each settles a different part of the multiple.
Capital-Efficiency Levers
Three disclosure or capital-policy levers visible in the filings. Each could reweight the multiple without requiring higher earnings.
Scenario Pathways
Three internally-consistent scenarios across the next four quarters. Each describes a different set of disclosure and operating outcomes — no single scenario is forecast; they are analytical bookends.
- Organic HRMOS ARR growth at Q3 lands below 12% YoY after consolidation back-out.
- FY7/26 guidance revised to group OPM ≤ 22% on Incubation spend.
- BizReach revenue growth below +10% YoY for two consecutive quarters.
- No buyback signal at Q4 / full-year release.
- Q3 release includes organic HRMOS ARR growth in the 18–25% YoY range.
- Group OPM holds at 24–26% for FY7/26 with the engine still funded.
- At least one quarter of Internal BizReach KPI disclosure by year-end.
- Net cash position acknowledged in capital-allocation language at full-year result.
- Organic HRMOS ARR growth disclosed at ≥ 25% YoY, sonar consolidation broken out.
- Group OPM holds ≥ 26% for FY7/26 with KPI table for Internal BizReach.
- Buyback authorisation ≥ ¥10bn over 24 months or formula-based return policy.
- BizReach revenue ≥ +15% YoY through any domestic hiring dip.
This is not investment advice.
Japan Investor Interface Co., Ltd. ("JII") is an investor-relations (IR) consultancy. JII is not a registered investment advisor, financial advisor, broker-dealer, or securities firm in any jurisdiction. JII is not registered as a Financial Instruments Business Operator (金融商品取引業者) under Japan's Financial Instruments and Exchange Act. JII does not have a 投資助言・代理業 registration and does not provide investment advice or solicit the purchase, sale, or holding of any security.
JII Compounders is an editorial publication. Each profile is an analytical study of how publicly disclosed information about a Japanese listed company has been received by the market. It is intended for educational and research purposes for IR professionals, finance students, journalists, and other readers interested in corporate disclosure practice. Nothing in this publication constitutes a recommendation, opinion, suggestion, or solicitation to buy, sell, or hold any security, derivative, or other financial instrument. Price targets, scenario ranges, multiples, and comparable-company references are illustrative of analytical method only and must not be interpreted as JII's investment opinion. JII does not have an investment opinion on any security discussed.
No reliance. The information presented may be incomplete, out of date, or incorrect. Forward-looking statements are inherently uncertain. Past price performance does not indicate future results. Estimates and scenario figures are not predictions and may not be achieved. JII makes no representation or warranty, express or implied, regarding the accuracy, completeness, timeliness, or reliability of any information in this publication.
No fiduciary or advisory relationship. Reading this publication does not create any advisory, fiduciary, or professional relationship between you and JII. Before making any investment, tax, accounting, legal, or other decision, you should consult qualified, licensed advisors in your jurisdiction and conduct your own independent due diligence based on primary disclosures issued by the company concerned.
Conflicts & positions. JII may provide paid IR diagnostic, translation, or interpretation services to Japanese listed companies, including companies discussed in this publication. JII does not trade in or hold positions in the securities of companies profiled. Where a JII engagement exists with a profiled company, that fact will be disclosed at the top of the profile.
Trademarks & data. Company names, logos, tickers, and product names referenced are the property of their respective owners. Share-price data is licensed from third-party providers. TradingView is a trademark of TradingView, Inc. All rights reserved.
本資料は、日本の金融商品取引法に基づく投資助言・代理業ではなく、特定の有価証券の売買その他の取引の勧誘・推奨を目的とするものではありません。本資料は教育・研究を目的とした分析記事であり、JII（株式会社ジャパン・インベスター・インターフェース）は、本資料の内容に基づく投資判断について一切の責任を負いません。投資の判断はご自身の責任と独立した調査に基づいて行ってください。